Effect of inhaled H₁ and H₂ receptor antagonists in normal and asthmatic subjects

NEIL C THOMSON AND JAMES W KERR

From the Department of Respiratory Medicine, Western Infirmary, Glasgow

ABSTRACT The effects on airflow resistance of an inhaled H₁ receptor antagonist, clemastine, and an H₂ receptor antagonist, cimetidine, have been investigated in normal and asthmatic subjects. No significant changes in specific conductance (sGaw) were seen in six normal subjects. In eight asthmatic subjects a significant increase in forced expiratory volume in one second (FEV₁) occurred at 60 min (<0.02), 90 min (<0.02), and 120 min (<0.05) after the inhalation of clemastine, whereas inhaled cimetidine had no effect on airflow resistance. Clemastine and cimetidine were tested on histamine-induced bronchoconstriction in eight normal and eight asthmatic subjects. Clemastine significantly reduced the fall in sGaw in normal subjects and the fall in FEV₁ in asthmatic subjects, whereas cimetidine had no protective effect. Clemastine and ipratropium bromide were tested on methacholine-induced bronchoconstriction in eight normal subjects. Ipratropium bromide, but not clemastine, significantly reduced the fall in sGaw after methacholine. These results suggest that in normal and asthmatic subjects histamine-induced bronchoconstriction is mediated predominantly via H₁ rather than H₂ receptors in the airways.

Histamine is released when sensitised human lung tissue interacts with specific antigen *in vitro*.¹ Evidence for histamine acting as a chemical mediator in asthma is based on reports of raised histamine levels after oral aspirin challenge,² exercise challenge,³ allergen challenge,⁴ and spontaneously occurring asthma.⁵ In experimental animals, histamine has been shown to constrict airway smooth muscle by a direct local effect,⁶ and also by a reflex vagal pathway.⁷ In normal and asthmatic subjects, however, histamine acts mainly by direct stimulation of bronchial smooth muscle.⁸⁻¹¹ In other tissues of the body, two types of histamine receptor have been identified.¹²⁻¹³ Smooth muscle contraction is mediated by H₁ receptors, while H₂ receptor responses involve gastric acid secretion and cardiac stimulation. Vasodilation is mediated by both H₁ and H₂ receptors.¹⁴ Recent *in vitro* studies¹⁵ have indicated that H₁ and H₂ receptors are present in human bronchial smooth muscle.

The purpose of this study was to investigate whether H₁ or H₂ receptor responses or both are

present on the airways of normal and asthmatic subjects.

Methods

Seventeen patients, aged 16-45 years, with extrinsic asthma and reversible airflow obstruction were studied. All had positive skin tests to inhalant allergens. Sodium cromoglycate and bronchodilators were discontinued for 12 hours before each test was carried out. Patients on oral or aerosol corticosteroids were excluded from the study. All patients were non-smokers. Their baseline data are represented in the table. Eight normal subjects, aged 22-36 years, with no history of chronic respiratory disease were also studied, three of whom smoked 10-15 cigarettes per day. The nature and the purpose of the study were explained to both patients and normal subjects. The investigations were approved by the Ethical Committee of this hospital and all patients and normal subjects gave informed consent.

Airways resistance (Raw) and thoracic gas volume were measured simultaneously in a constant volume body plethysmograph (Fen-vent and Gut). The results were expressed as specific

Address for reprint requests: Dr NC Thomson, Regional Chest and Allergy Unit, Unit, St Joseph's Hospital and McMaster University, Hamilton, Ontario, Canada.

Table 1 Baseline data of asthmatic subjects

Subject	Sex	Age (yr)	Mean baseline FEV ₁	Percentage predicted FEV ₁
	F	17	3.24	106.2
12	M	21	4.20	109.0
3	F	31	3.00	98.3
4	M	25	3.82	81.2
5	M	18	4.16	101.4
6	F	26	2.63	87.6
7	F	19	2.23	81.7
8	M	24	4.66	112.2
9	F	36	1.71	63.3
10	M	17	2.60	72.2
11	F	28	4.13	121.4
12	M	45	4.26	118.3
13	M	24	5.36	120.4
14	M	30	4.01	109.8
15	M	34	2.33	65.6
16	F	34	2.75	94.8
17	F	16	2.57	85.6

conductance (sGaw) which is the reciprocal of airways resistance per litre of thoracic gas volume. The mean of six values recorded was taken as sGaw. All plethysmographic measurements were carried out by one observer, but analysis of the records of pressure and flow was carried out by another person who was unaware of the nature or order of agents administered. Forced expiratory volume in one second (FEV₁) was measured in triplicate using a dry wedge spirometer (Vitalograph), the best recording being used for analysis. Where necessary volumes were corrected to body temperature, pressure saturated with water vapour (BTPS). Predicted normal values for FEV₁ were taken from Cotes.¹⁶

All solutions were inhaled through a Wright nebuliser (using compressed air at a flow rate of 8 l/min). The subject placed the nebuliser just outside the open mouth and took tidal breaths of the aerosol. The different aerosols were always inhaled by each subject on separate days. Subjects were unaware of the sequence of the aerosols which were randomly assigned.

EXPERIMENTAL PROCEDURES

Normal subjects

In six normal subjects, after baseline measurements of sGaw, saline (9 g/l), clemastine (1 g/l), or cimetidine (100 g/l) was inhaled through a Wright nebuliser for 5 min, sGaw then being recorded at 2, 5, 10, 20, 30, and 60 min.

In eight normal subjects measurements of sGaw were performed before and 30 min after inhaling saline (9 g/l), clemastine (1 g/l), or cimetidine (100 g/l) for 5 min. Five breaths of increasing concentrations of histamine dihydrochloride (1.5, 3.1, 6.2, 12.5, 25.0, 50.0 g/l) were

then inhaled every 3 min, with sGaw recorded at 2 min after each inhalation.

In a separate series of experiments in the same eight subjects, sGaw was measured before and 30 min after inhaling saline (9 g/l), clemastine (1 g/l), or ipratropium bromide (1 g/l) for 5 min. Five breaths of increasing concentrations of methacholine dihydrochloride (3.1, 6.2, 12.5, 25.0, 50.0 g/l) were then inhaled every 3 min, with sGaw recorded at 2 min after each inhalation.

Asthmatic subjects

In eight asthmatic subjects (numbers 1–8), after baseline measurements of FEV₁, saline (9 g/l) or clemastine (0.5 g/l) was inhaled for 5 min, FEV₁ being recorded at 30, 60, 90, and 120 min.

In a further eight asthmatic subjects (numbers 3–6, 8, 9, 16, 17), after baseline measurements of FEV₁, saline (9 g/l) or cimetidine (100 g/l) was inhaled for 5 min, FEV₁ then being recorded at 10, 30, 60, 90, and 120 min.

Finally in eight asthmatic subjects (numbers 10–17), FEV₁ was measured before and 30 min after inhaling saline (9 g/l), clemastine (0.5 g/l), or cimetidine (100 g/l) for 5 min. Five breaths of increasing concentrations of histamine dihydrochloride (0.15, 0.31, 0.62, 1.25, 2.5, 5.0 g/l) were then inhaled every 3 min, with FEV₁ recorded at 2 min after each inhalation.

The statistical significance of observed changes in sGaw was determined using the Wilcoxon matched-pairs signed-rank test and Fisher, Irwin, and Yates exact probability test (experiment involving six subjects only), and of observed changes in FEV₁ by student's *t* test. Differences were considered significant if *p* < 0.05.

Results

NORMAL SUBJECTS

In six subjects no significant difference was found in pretreatment sGaw, and there were no absolute changes in sGaw at 2, 5, 10, 20, 30, and 60 min after the inhalation of clemastine, cimetidine, or saline (fig 1).

In eight subjects there were no significant differences in pretreatment sGaw, or absolute changes in sGaw at 30 min after the inhalation of clemastine, cimetidine, or saline. The change in sGaw after pretreatment with clemastine was significantly smaller than the change in sGaw after pretreatment with saline after 25.0 g/l (*p* < 0.05) and 50.0 g/l (*p* < 0.01) of inhaled histamine or after pretreatment with cimetidine after 25.0 g/l (*p* < 0.05) and 50 g/l (*p* < 0.01) of inhaled

Fig 1 Effect of inhaled clemastine, cimetidine, and saline on absolute change in sGaw ($\pm$ SEM) in normal subjects ($n=6$). Mean baseline sGaw value ($S^{-1}kPa^{-1}$) before clemastine 1.50 ± 0.26 ; before cimetidine 1.33 ± 0.21 ; before saline 1.37 ± 0.28 .

histamine. After pretreatment with cimetidine and saline there was no significant difference in the change in sGaw at each dose of inhaled histamine (fig 2). In the same eight normal subjects inhaled ipratropium bromide produced a significant rise in sGaw ($p<0.01$), whereas inhaled clemastine and saline had no effect. The change in sGaw after pretreatment with ipra-

Fig 2 Absolute change in sGaw ($\pm$ SEM) plotted against cumulative log dose of inhaled histamine (g/l) in normal subjects ($n=8$) after pretreatment with clemastine, cimetidine, or saline. Mean sGaw value ($S^{-1}kPa^{-1}$) before and 30 min after clemastine (1.43 ± 0.16 baseline, 1.45 ± 0.16 after clemastine); cimetidine (1.41 ± 0.17 baseline, 1.38 ± 0.16 after cimetidine); saline (1.46 ± 0.19 baseline, 1.38 ± 0.13 after saline).

tropium bromide was significantly different from the change in sGaw after pretreatment with clemastine or saline after 12.5, 25.0 and 50.0 g/l of inhaled methacholine ($p<0.01$) (fig 3).

ASTHMATIC SUBJECTS

In eight asthmatic subjects (numbers 1–8) inhaled clemastine produced significant increases in FEV₁ at 60 min ($p<0.02$), 90 min ($p<0.02$) and 120 min ($p<0.05$) after the inhalation (fig 4). The maximum mean percentage increase in FEV₁ ($\pm$ 1SD) after clemastine (14.3 ± 9.7) was significantly greater than after saline (5.7 ± 3.7) ($p<0.02$). In a separate study in eight asthmatic subjects (numbers 3–6, 8, 9, 16, 17) there was no significant difference in the absolute change in FEV₁ after pretreatment with cimetidine or saline at 10, 30, 60, 90, and 120 min after the inhalation (fig 5).

In eight asthmatic subjects (numbers 10–17) there were no significant differences in pretreatment FEV₁ or absolute changes in FEV₁ at 30 min after the inhalation of clemastine, cimetidine, or saline. After pretreatment with cimetidine there was no significant difference in the change in FEV₁ at each dose of inhaled

Fig 3 Absolute change in sGaw ($\pm$ SEM) plotted against cumulative log dose of inhaled methacholine (g/l) in normal subjects ($n=8$) after pretreatment with clemastine, ipratropium bromide, or saline. Mean sGaw value ($S^{-1}kPa^{-1}$) before and 30 min after clemastine (1.54 ± 0.22 baseline, 1.62 ± 0.25 after clemastine); ipratropium bromide (1.56 ± 0.24 baseline, 1.98 ± 0.30 after ipratropium bromide); saline (1.55 ± 0.23 baseline, 1.58 ± 0.21 after saline).

Fig 4 Effect of inhaled clemastine and saline on absolute change in FEV_1 ($\pm$ SEM) in asthmatic subjects ($n=8$). Mean baseline FEV_1 (l) value before clemastine 3.50 ± 0.30 ; before saline 3.54 ± 0.32 .

Fig 5 Effect of inhaled cimetidine and saline on absolute change in FEV_1 ($\pm$ SEM) in asthmatic subjects ($n=8$). Mean baseline FEV_1 (l) value before cimetidine 3.15 ± 0.36 ; before saline 3.20 ± 0.33 .

histamine when compared to that after pretreatment with saline. The change in FEV_1 after pretreatment with clemastine was significantly smaller than the change after pretreatment with saline after 0.62 g/l ($p<0.01$), 1.25 g/l ($p<0.01$), 2.5 g/l ($p<0.01$) of inhaled histamine or after pretreatment with cimetidine after 0.31 g/l ($p<0.02$), 0.62 g/l ($p<0.05$), 1.25 g/l ($p<0.02$), 2.5 g/l ($p<0.01$) of inhaled histamine (fig 6). Because only three patients were able to inhale histamine at a concentration of 5.0 g/l after pretreatment with saline or cimetidine, statistical comparison with the changes in FEV_1 after pretreatment with clemastine was not possible,

Fig 6 Absolute change in FEV_1 ($\pm$ SEM) plotted against cumulative log dose of inhaled histamine (g/l) in asthmatic subjects ($n=8$) after pretreatment with clemastine, cimetidine, or saline. Mean FEV_1 (l) before and 30 min after clemastine (3.46 ± 0.38 baseline, 3.66 ± 0.38 after clemastine); cimetidine (3.47 ± 0.36 baseline, 3.51 ± 0.36 after cimetidine); saline (3.59 ± 0.40 baseline, 3.60 ± 0.39 after saline).

although in each case the changes in FEV_1 after clemastine were much smaller than those after saline or cimetidine. In each of the eight asthmatic patients studied, the cumulative log histamine dose-response curve was shifted to the right after pretreatment with clemastine in comparison to after pretreatment with saline or cimetidine (fig 7).

Discussion

At least two types of histamine receptor are involved in the histamine response.¹² Clemastine is an extremely potent and specific H1 receptor antagonist with no central or circulatory effects in conscious animals.¹⁷ It possesses no significant anticholinergic or antiserotonin activity.^{18,19} The concentration of clemastine inhaled by the asthmatics was half that administered to the normal subjects, since a concentration of greater than 0.5 g/l was found to produce upper airway irritation. H2 receptor responses are blocked by burimamide, metiamide, and cimetidine but not by H1 receptor antagonists clemastine and chlorpheniramine.¹⁸ Cimetidine is a specific competitive H2 receptor antagonist with no significant interaction at catecholamine β -receptors, H1 receptors or muscarinic receptors.²⁰ The concentration of cimetidine used in this study

Fig 7 Absolute values of FEV₁ plotted against cumulative log dose of inhaled histamine (g/l) for each of the eight asthmatic subjects studied. Values of FEV₁ are shown after pretreatment with clemastine (▲), cimetidine (●), or saline (○).

has been shown to inhibit effectively H₂ responses such as gastric acid secretion in humans.²¹

The absence of any significant change in airways calibre of normal subjects after an inhaled H₁ receptor antagonist suggests that this receptor is not important in the maintenance of normal airways tone. Several H₁ receptor antagonists, however, have been reported to cause bronchodilation in asthmatic patients. Popa²² found increases in the airways calibre of 10 asthmatic patients after intravenously administered chlorpheniramine (10mg) although this was complicated by drowsiness in several subjects. Nogrady *et al.*²³ reported that inhaled clemastine produced a maximum percentage increase in FEV₁ of 21% in 12 asthmatic

patients, in comparison to an increase of 14% found in this study. Although the dose and method of administration of clemastine were similar, the better baseline function of the patients in the present study may account for the smaller increase in FEV₁ after clemastine. The reason for the difference in response to an inhaled H₁ antagonist between normal subjects and patients with asthma is unexplained but may indicate continuous release of histamine in the asthmatic group as has recently been suggested.²⁴

In experimental animals, histamine acts locally on the airway smooth muscle causing constriction⁶ and can also stimulate vagal sensory receptors in the airways causing reflex bronchoconstriction.⁷ In normal subjects and patients

with asthma, however, the main action of histamine is probably direct stimulation of human bronchial smooth muscle⁸⁻¹¹ via H1 or H2 receptors or both. The protective action of the H1 receptor antagonist clemastine on histamine-induced bronchoconstriction in asthmatic subjects confirms the findings of Nogrady and Bevan²⁴ and extends this observation to normal subjects. These findings, therefore, suggest that histamine was acting at the H1 receptor in both normal subjects and asthmatic patients. A similar reduction in bronchoconstrictor effect of histamine has also been reported with less potent or specific H1 receptor antagonists than clemastine.^{7 25 26} H1 receptor antagonists may possess to a variable degree anticholinergic and local anaesthetic effects.²⁷ In the present study, clemastine had no significant anticholinergic action in normal subjects and has been shown to have no protective effect on methacholine-induced bronchoconstriction in asthmatics.²⁴ A local anaesthetic effect by clemastine on sensory irritant receptors is also unlikely. Firstly, anticholinergic drugs only slightly reduce the airway response to histamine in comparison to H1 receptor antagonists.⁸⁻¹¹ Secondly, the inhaled local anaesthetic bupivacaine has no preventive action on histamine-induced bronchoconstriction in normal subjects.¹⁰ Changes in baseline airflow obstruction may alter bronchial reactivity.²⁸ This is unlikely, however, to be relevant to the present study, since although clemastine causes bronchodilation in asthmatic patients, this is only slight at 30 min after inhaled clemastine when histamine challenge was performed. Furthermore, in normal subjects clemastine displaced the histamine dose response curve when there was no change in baseline lung function. The most likely explanation for our findings is that there are H1 receptors in human airways.

The present results do not support the hypothesis that H2 receptors are present in the airways of normal subjects and asthmatics.²⁹ Slight changes in small airways function, however, could have been missed by measurement of specific conductance in normal subjects and FEV₁ in asthmatic patients. Eyre³⁰ showed that the relaxant effect of histamine on sheep terminal bronchus was an H2 response. In atopic and non-atopic human subjects, however, inhaled histamine caused bronchoconstriction of both large and small airways.³¹ It is unknown whether the dose of cimetidine inhaled in this study was sufficient to produce complete H2 receptor blockade. The inhalation technique, however, used to give cimetidine and histamine should have

resulted in a similar degree of aerosol deposition within the airways, even if their sites of action were different. Differences have been found between cimetidine and other H2 receptor blockers in their ability to reduce mediator release from sensitised tissue,³² burimamide and metiamide but not cimetidine increasing the anaphylactic reactions in sensitised guinea pigs. It is not known whether any possible difference between cimetidine and other H2 receptors blockers would be relevant to the identifications of human bronchial smooth muscle H2 receptors. Finally, in some experimental systems, H2 antagonists have no effect alone, but act synergistically when combined with H1 antagonists.³³ A similar synergistic action in bronchial smooth muscle cannot be excluded from this study.

If histamine is shown to be an important mediator of immediate type hypersensitivity in human asthma, then the predominant site of action of histamine is probably by a direct effect on bronchial smooth muscle H1 receptors.

We acknowledge gratefully the technical help of Mrs R Jack.

References

- 1 Austen KF, Orange RP. Bronchial asthma: the possible role of the chemical mediators of immediate hypersensitivity in the pathogenesis of subacute chronic disease. *Am Rev Respir Dis* 1975; **112**:423-36.
- 2 Stevenson DD, Arroyave CM, Bhat KN, Tan EM. Oral ASA challenges in asthmatic patients: a study of plasma histamine. *Clin Allergy* 1976; **6**:493-505.
- 3 Ferris L, Anderson SD, Temple DM. Histamine release in exercise-induced asthma. *Br Med J* 1978; **2**:1697.
- 4 Bhat KN, Arroyave CM, Marney SR, Stevenson DD, Tan EM. Plasma histamine changes during provoked bronchospasm in asthmatic patients. *J Allergy Clin Immunol* 1976; **58**:647-56.
- 5 Simon RA, Stevenson DD, Arroyave CM, Tan EM. The relationship of plasma histamine to the activity of bronchial asthma. *J Allergy Clin Immunol* 1977; **60**:312-6.
- 6 Dale HH, Laidlaw PP. The physiological action of B-iminazolyethylamine. *J Physiol (London)* 1910-11; **41**:318-44.
- 7 Gold WM, Kessler GF, Yu DYC. Role of vagus nerves in experimental asthma in allergic dogs. *J Appl Physiol* 1972; **33**:719-25.
- 8 Casterline CL, Evans R, Ward GW. The effect of atropine and albuterol aerosols on the human bronchial response to histamine. *J Allergy Clin Immunol* 1976; **58**:607-13.
- 9 Cockcroft DW, Killian DN, Mellon JJA, Har-

- greave FE. Protective effect of drugs on histamine-induced asthma. *Thorax* 1977; **32**: 429–37.
- 10 Thomson NC. The effect of different pharmacological agents on respiratory reflexes in normal and asthmatic subjects. *Clin Sci* 1979; **56**:235–41.
 - 11 Woenne R, Kattan M, Orange RP, Levison H. Bronchial hyperreactivity to histamine and methacholine in asthmatic children after inhalation of SCH1000 and chlorpheniramine maleate. *J Allergy Clin Immunol* 1978; **62**: 119–24.
 - 12 Ash ASF, Schild HO. Receptors mediating some actions of histamine. *Br J Pharmacol* 1966; **27**: 427–39.
 - 13 Black JW, Duncan WAM, Durant CJ, Ganellin CR, Parsons ME. Definition and antagonism of histamine H_2 receptors. *Nature (London)* 1972; **236**:385–90.
 - 14 Black JW, Owen DA, Parsons ME. An analysis of the depressor responses to histamine in the cat and dog; involvement of H_1 and H_2 receptors. *Br J Pharmacol* 1975; **54**:319–24.
 - 15 Dunlop LS, Smith AP. The effect of histamine antagonists on antigen-induced contractions of sensitized human bronchus in vitro. *Br J Pharmacol* 1977; **59**:475P.
 - 16 Cotes JE. *Lung function*. Third edition. Oxford: Blackwell, 1975: 380.
 - 17 Römer D, Weidmann H. Pharmacological studies in the new antihistamine Tavegil. *Med Welt* 1966; **17**:2791–4.
 - 18 Kallós P. Laboratory and clinical investigations of the antihistamine clemastine (Tavegil). *Clin Trials J* 1971; **8**:23–6.
 - 19 Weidmann H, Grauwiler J, Griffith R, Römer D, Taeschler M, Zehnder K. Farmacologia, farmacocinetica e tossicologia del nuovo antistaminico H S592 (Tavegil). *Boll Chim Farmaceut* 1967; **106**:467–96.
 - 20 Parsons ME. In: Burland WL, Simkins MA (eds). *Cimetidine. Proceedings of the Second International Symposium on Histamine H_2 -receptor antagonists*. Amsterdam: Excerpta Medica 1977: 13.
 - 21 Hirschowitz BI. H_2 Histamine receptors. *Ann Rev Pharmacol Toxicol* 1979; **19**:203–44.
 - 22 Popa VT. Bronchodilating activity of an H_1 blocker chlorpheniramine. *J Allergy Clin Immunol* 1977; **59**:54–63.
 - 23 Nogrady SG, Hartley JPR, Hanslip PDJ, Hurst NP. Bronchodilation after inhalation of the antihistamine clemastine. *Thorax* 1978; **33**:479–82.
 - 24 Nogrady SG, Bevan C. Inhaled antihistamines—bronchodilation and effects on histamine—and methocholine-induced bronchoconstriction. *Thorax* 1978; **33**:700–4.
 - 25 Eiser NM, Guz A, Snashall PD. H_1 and H_2 receptor antagonists on bronchial dose-response curves to histamine in normal subjects. *Clin Sci Molec Med* 1978; **54**:10P–11P.
 - 26 Casterline CL, Evans R. Further studies on the mechanism of human histamine-induced asthma. *J Allergy Clin Immunol* 1977; **59**:420–4.
 - 27 Douglas WW. In: Goodman LS, Gilman A (eds). *The pharmacological basis of therapeutics*. Fifth edition. New York: Macmillan, 1975: 590.
 - 28 Benson MK. Bronchial hyperreactivity. *Br J Dis Chest* 1975; **69**:227–39.
 - 29 Busse WW, Sosman J. Decreased H_2 histamine response of granulocytes of asthmatic patients. *J Clin Invest* 1977; **59**:1080–7.
 - 30 Eyre P. Histamine H_2 receptors in the sheep bronchus and cat trachea: the action of burimamide. *Br J Pharmacol* 1973; **48**:321–3.
 - 31 Brown NE, McFadden ER, Ingram RH. Airway responses to inhaled histamine in asymptomatic smokers and nonsmokers. *J Appl Physiol* 1977; **42**:508–13.
 - 32 Drazen JM, Venugopalan CS, Soter NA. H_2 receptor mediated inhibition of immediate type hypersensitivity reactions in vivo. *Am Rev Respir Dis* 1978; **117**:479–84.
 - 33 Powell JR, Brody MJ. Participation of H_1 and H_2 histamine receptors in physiological vasodilator responses. *Am J Physiol* 1976; **231**: 1002–9.